Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.
about
Orchestrating epigenetic roles targeting ocular tumorsRegulation of tumor metastasis by myeloid-derived suppressor cellsMicroRNA dysregulation in uveal melanoma: a new player enters the gameTumor-induced myeloid dysfunction and its implications for cancer immunotherapyRegulation of cancer metastasis by cell-free miRNAs.Biology of advanced uveal melanoma and next steps for clinical therapeutics.Assay reproducibility in clinical studies of plasma miRNAComparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression.A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomasmiRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications.MicroRNA-155-IFN-γ Feedback Loop in CD4(+)T Cells of Erosive type Oral Lichen Planus.MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancerCirculating miR-21, miR-378, and miR-940 increase in response to an acute exhaustive exercise in chronic heart failure patientsOncogenic role of microRNA‑20a in human uveal melanoma.MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approachesSurgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.The biology of uveal melanomaMiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer.miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancerNeutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells.Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.Circulating MicroRNAs as Biomarkers and Mediators of Cell-Cell Communication in Cancer.Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression
P2860
Q26751251-EA91405D-6631-4704-B8D0-7CC909D6DD26Q27022125-672F9475-6D09-4428-AC95-32EF690E2F79Q27026746-ABBB0CD2-77EB-429B-BD6F-A5F2F1A72083Q34810257-CDE227CF-FE83-41D4-8F7E-5F6558908651Q35034340-B678853D-F139-46D9-A832-BFBE05B87921Q35079709-E76BA2B2-59CA-4E4C-8D53-C77878EC23CDQ35325816-9280BE97-CA11-4A19-8ACE-5620DD3047A6Q35828512-2B0EAE4E-21BA-4DC2-BCDD-8CF9FBE43904Q35853997-69EB3C21-4CD1-4D58-AB99-BCD9903DFC7FQ36091092-8F87466A-990E-4AFA-A9E2-60DD62D67F01Q36213467-E136AA06-8826-4F11-AAB4-7A9D674BA154Q36305539-6CF694D9-5133-4E45-B908-852AB18EAC5AQ36738904-1F2D1BB3-2ACA-4D15-A90A-2CDDAB66F753Q37022196-13EF186D-5296-46BA-8A8C-F08A797664BCQ37082920-B99341EF-0524-4948-92FD-EA59D1D4E840Q37305975-76607401-8959-42A3-B635-1C3B106F3FAAQ37725564-6929CF91-2AEB-4BB5-8ABB-BCA4F8B48185Q37742632-9FFD67E7-1C36-47C1-86EB-7F58BC5E23E0Q38927623-B9F7EF25-8AD0-4FC6-8915-C3132350639EQ41143092-074165C8-E46B-4D97-AC11-A23192B25A09Q47563950-9866F7DC-AFA4-41E3-ABB6-04AD20E7087BQ47736139-8DE7CDCF-0336-4843-BE9E-F46AE7F3DF78Q48092810-B0DCCA87-2F72-414E-A748-1F8BC9505271Q50102994-BDF67FCB-B800-4568-A4CA-437E2CAB2A0EQ53845923-CDDD9672-955C-46DD-ABE4-A5E2A29CE037Q55428812-FD516FCB-0996-49B4-984B-575397ACCB66Q58122058-3C3C32DB-8E15-4821-B954-C80CE939CE8B
P2860
Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Circulating immune cell and mi ...... developing metastatic disease.
@ast
Circulating immune cell and mi ...... developing metastatic disease.
@en
Circulating immune cell and mi ...... developing metastatic disease.
@nl
type
label
Circulating immune cell and mi ...... developing metastatic disease.
@ast
Circulating immune cell and mi ...... developing metastatic disease.
@en
Circulating immune cell and mi ...... developing metastatic disease.
@nl
prefLabel
Circulating immune cell and mi ...... developing metastatic disease.
@ast
Circulating immune cell and mi ...... developing metastatic disease.
@en
Circulating immune cell and mi ...... developing metastatic disease.
@nl
P2093
P2860
P1433
P1476
Circulating immune cell and mi ...... developing metastatic disease
@en
P2093
John W Crabb
Pierre L Triozzi
Raymond Tubbs
Susan Achberger
Wayne Aldrich
P2860
P304
P356
10.1016/J.MOLIMM.2013.11.018
P50
P577
2013-12-25T00:00:00Z